We found that in subjects with CN-AML and NPM1 mutation, those with ≥1 high-risk co-variate, including positive MRD test after the second consolidation cycle, DNMT3A mutation, FLT3-ITD mutation with high VAF and DDX11 mutation, had a higher CIR and worse LFS compared to subjects without these co-variates. The gene discussed is DNMT3A; the disease is acute myeloid leukemia.